Etanercept-synthesizing adipose-derived stem cell secretome: A promising therapeutic option for inflammatory bowel disease

Figure 5 Possible anti-inflammatory mechanism of etanercept-secretome in inflammatory bowel disease. The therapeutic efficacy of Etanercept in treating inflammatory bowel disease (IBD) exhibits variability, likely due to the complex and multifactorial nature of IBD, which involves a multitude of pro-inflammatory factors beyond tumor necreosis factor-α. This complexity suggests the need for a multi-targeted therapeutic approach. In contrast, etanercept-secretome (Et-Sec) is obtained from genetically modified adipose-derived stem cells capable of producing both etanercept and a diverse secretome characterized by anti-inflammatory and immunomodulatory attributes. This unique composition raises the possibility that Et-Sec may possess enhanced effectiveness in suppressing the inflammatory mechanisms associated with IBD when compared to the use of etanercept alone. IBD: Inflammatory bowel disease; ASCs: Adipose-derived stem cells.